Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coenzyme q10 + trastuzumab
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy where coenzyme Q10 (CoQ10) is administered alongside trastuzumab to reduce cardiotoxicity in HER2-positive breast cancer patients. CoQ10 provides cardioprotection by increasing ejection fraction and decreasing inflammatory biomarkers and cardiac enzyme levels, allowing patients to continue beneficial trastuzumab therapy with reduced cardiac side effects.
- Other names
- ubiquinone + trastuzumab
02
Targets
Mitochondrial electron transport chain complexes and cellular lipid membranesERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on coenzyme q10 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coenzyme q10 + trastuzumab.